Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

Seeking Alpha / 8 hours ago 1 Views

- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - 
- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile -
Read more

Comments